PART I - FINANCIAL INFORMATION [Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) Unaudited interim financial statements show significant growth in assets, revenue, and net income, with strong operational cash flow despite cash used for acquisitions [Consolidated Balance Sheets](index=5&type=section&id=Consolidated%20Balance%20Sheets) Total assets increased to $2.24 billion as of September 30, 2021, driven by acquisitions, with a corresponding rise in liabilities and stockholders' equity Consolidated Balance Sheet Highlights (in thousands) | Account | Sep 30, 2021 | Dec 31, 2020 | | :--- | :--- | :--- | | **Total Assets** | **$2,241,397** | **$1,902,887** | | Cash and cash equivalents | $621,098 | $717,292 | | Inventories, net | $156,163 | $95,025 | | Intangible assets, net | $340,163 | $287,100 | | Goodwill | $833,559 | $618,305 | | **Total Liabilities** | **$526,132** | **$373,737** | | Noncurrent contingent consideration | $79,962 | $0 | | **Total stockholders' equity** | **$1,715,265** | **$1,529,150** | [Consolidated Statements of Comprehensive Income](index=6&type=section&id=Consolidated%20Statements%20of%20Comprehensive%20Income) The company reported significant year-over-year growth in revenue and profitability for both the quarter and nine-month period ended September 30, 2021 Financial Performance (in thousands, except per share data) | Metric | Q3 2021 | Q3 2020 | % Change | Nine Months 2021 | Nine Months 2020 | % Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Total Revenue | $178,216 | $94,060 | 89.5% | $484,013 | $257,612 | 87.9% | | Income from Operations | $45,194 | $20,961 | 115.6% | $129,817 | $52,404 | 147.7% | | Net Income | $33,498 | $14,552 | 129.9% | $99,181 | $40,228 | 146.5% | | Diluted EPS | $0.58 | $0.27 | 114.8% | $1.74 | $0.75 | 132.0% | [Consolidated Statements of Stockholders' Equity](index=7&type=section&id=Consolidated%20Statements%20of%20Stockholders%27%20Equity) Total stockholders' equity increased to $1.72 billion, primarily driven by net income and common stock issuance for the Avitide acquisition - Key drivers for the increase in stockholders' equity during the first nine months of 2021 were net income of **$99.2 million** and stock-based compensation of **$20.5 million**[15](index=15&type=chunk) - The company issued **271,096** shares of common stock valued at **$77.6 million** as part of the consideration for the acquisition of Avitide Inc[15](index=15&type=chunk) [Consolidated Statements of Cash Flows](index=9&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Net cash from operations increased, but significant cash used in investing activities, primarily for acquisitions, led to an overall decrease in cash and cash equivalents Cash Flow Summary (Nine Months Ended Sep 30, in thousands) | Activity | 2021 | 2020 | | :--- | :--- | :--- | | Net cash provided by operating activities | $69,396 | $47,754 | | Net cash used in investing activities | ($158,893) | ($43,097) | | Net cash provided by financing activities | $730 | $7,078 | | **Net (decrease) increase in cash** | **($96,194)** | **$15,895** | - Cash used for acquisitions, net of cash acquired, was **$121.0 million** in the first nine months of 2021, a significant increase from **$28.4 million** in the same period of 2020[18](index=18&type=chunk) [Notes to Unaudited Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Unaudited%20Consolidated%20Financial%20Statements) The notes provide detailed disclosures on accounting policies, recent acquisitions, asset composition, convertible notes, and segment reporting [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=36&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes strong financial performance to robust demand and strategic acquisitions, maintaining a strong liquidity position despite significant investment outflows [Acquisitions](index=36&type=section&id=Acquisitions) Repligen completed key acquisitions of Avitide and Polymem in 2021, expanding capabilities in affinity ligand development and hollow fiber manufacturing - **Avitide, Inc. Acquisition (Sep 2021):** Acquired for its leading technology in affinity ligand discovery and development, aiming to expand Repligen's proteins franchise to address purification needs of gene therapies and other emerging modalities[133](index=133&type=chunk)[134](index=134&type=chunk) - **Polymem S.A. Acquisition (Jul 2021):** Acquired to expand the portfolio of hollow fiber systems and consumables, substantially increasing membrane and module manufacturing capacity and establishing a center of excellence in Europe[135](index=135&type=chunk)[136](index=136&type=chunk) [Results of Operations](index=37&type=section&id=Results%20of%20Operations) Revenue for the nine months increased by 87.9% to $484.0 million, driven by strong product demand, while operating expenses also rose significantly Revenue Breakdown (in thousands) | Period | Product Revenue | % Change YoY | Total Revenue | % Change YoY | | :--- | :--- | :--- | :--- | :--- | | **Q3 2021** | $178,177 | 89.5% | $178,216 | 89.5% | | **Nine Months 2021** | $483,834 | 87.9% | $484,013 | 87.9% | - Product revenue growth was driven by robust demand for filtration and proteins products, accelerated demand related to COVID-19 vaccines and therapeutics, and increased demand for gene therapy and monoclonal antibody manufacturing[147](index=147&type=chunk) Operating Expense Changes (Nine Months 2021 vs 2020) | Expense Category | % Change YoY | | :--- | :--- | | Cost of product revenue | 81.8% | | Research and development | 86.9% | | Selling, general and administrative | 58.3% | [Non-GAAP Financial Measures](index=41&type=section&id=Non-GAAP%20Financial%20Measures) Non-GAAP financial measures are provided to offer a clearer view of operational performance by excluding specific non-recurring or non-cash items Reconciliation of GAAP to Non-GAAP Adjusted Net Income (Nine Months Ended Sep 30, 2021) | Description | Amount (in thousands) | Per Share | | :--- | :--- | :--- | | **GAAP net income** | **$99,181** | **$1.74** | | Inventory step-up charges | $1,868 | $0.03 | | Acquisition and integration costs | $11,593 | $0.20 | | Intangible amortization | $16,001 | $0.28 | | Non-cash interest expense | $8,592 | $0.15 | | Tax effect of non-GAAP charges | ($8,904) | ($0.16) | | **Non-GAAP adjusted net income** | **$128,337** | **$2.25** | Adjusted EBITDA (in thousands) | Period | Q3 2021 | Q3 2020 | Nine Months 2021 | Nine Months 2020 | | :--- | :--- | :--- | :--- | :--- | | **Adjusted EBITDA** | **$60,516** | **$29,416** | **$168,939** | **$78,032** | [Liquidity and Capital Resources](index=43&type=section&id=Liquidity%20and%20Capital%20Resources) The company maintains a strong liquidity position with $621.1 million in cash, sufficient for future needs despite significant cash outflows for acquisitions - The company held **$621.1 million** in cash and cash equivalents at September 30, 2021, down from **$717.3 million** at December 31, 2020[172](index=172&type=chunk) Cash Flow Summary (Nine Months Ended Sep 30, 2021, in thousands) | Activity | Cash Flow | | :--- | :--- | | Operating activities | $69,396 | | Investing activities | ($158,893) | | Financing activities | $730 | - The company believes its current cash balances are adequate to meet cash needs for at least the next **24 months**, absent further acquisitions[187](index=187&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=48&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risks are interest rates and foreign currency exchange, with no hedging currently employed for foreign currency exposure - The company has no investments in commercial paper, government securities, or corporate bonds as of September 30, 2021, thus a hypothetical **100 basis point** interest rate increase would have no effect on its cash position[195](index=195&type=chunk) - Primary foreign currency exposures include the Swedish krona, Euro, and British pound. The company does not currently use hedging instruments to manage this risk[197](index=197&type=chunk) [Controls and Procedures](index=48&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective, with the assessment of internal controls excluding recently acquired businesses - Management concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level as of the end of the quarter[198](index=198&type=chunk) - The scope of the assessment of internal control over financial reporting for Q3 2021 does not include the recently acquired Polymem and Avitide businesses[199](index=199&type=chunk) PART II - OTHER INFORMATION [Legal Proceedings](index=50&type=section&id=Item%201.%20Legal%20Proceedings) The company reports no material legal proceedings or claims that would adversely affect its operations or financial condition - As of the filing date, the company reports no **material** legal proceedings[201](index=201&type=chunk) [Risk Factors](index=50&type=page&id=Item%201A.%20Risk%20Factors) No material changes to previously disclosed risk factors from the annual report are reported - No **material** changes to risk factors from the Form 10-K for the period ended December 31, 2020 are reported[202](index=202&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=50&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company issued unregistered common stock valued at $77.6 million for the Avitide acquisition, exempt under Rule 506(b) of Regulation D - As part of the Avitide acquisition, the company issued **271,096** unregistered shares of common stock valued at **$77.6 million**[203](index=203&type=chunk) [Exhibits](index=51&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including certifications and XBRL data files [Signatures](index=52&type=page&id=Signatures) The report is duly signed by the President and CEO, and the CFO, on October 28, 2021

Repligen Corporation (NASDAQ:RGEN) Q3 2021 Earnings Conference Call October 28, 2021 8:30 AM ET Company Participants Sondra Newman - Head of Investor Relations Anthony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants Daniel Arias - Stifel, Nicolaus & Company, Inc. Julia Qin - JPMorgan Chase & Co. Puneet Souda - SVB Leerink LLC Jacob Johnson - Stephens Inc. Paul Knight - KeyBanc Capital Markets Inc. Christine Rains - William Blair & Company Matt ...

PART I [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents Repligen Corporation's unaudited interim consolidated financial statements, including balance sheets, income statements, equity statements, cash flow statements, and related notes [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) Total assets increased to **$2.016 billion**, driven by cash, receivables, and inventories, while liabilities rose to **$412.9 million** and equity to **$1.603 billion** Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2021 | December 31, 2020 | | :--- | :--- | :--- | | **Total Current Assets** | $983,830 | $902,382 | | **Total Assets** | $2,015,965 | $1,902,887 | | **Total Current Liabilities** | $332,342 | $318,956 | | **Total Liabilities** | $412,896 | $373,737 | | **Total Stockholders' Equity** | $1,603,069 | $1,529,150 | [Consolidated Statements of Comprehensive Income](index=5&type=section&id=Consolidated%20Statements%20of%20Comprehensive%20Income) Total revenue for Q2 2021 increased **86.3%** to **$163.0 million**, with net income reaching **$36.2 million**, and for H1 2021, revenue grew **87.0%** to **$305.8 million**, yielding **$65.7 million** in net income Financial Performance (in thousands, except per share data) | Metric | Three Months Ended June 30, 2021 | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :--- | :--- | :--- | :--- | :--- | | **Total Revenue** | $162,960 | $87,462 | $305,797 | $163,552 | | **Income from Operations** | $48,240 | $19,537 | $84,623 | $31,443 | | **Net Income** | $36,233 | $15,861 | $65,683 | $25,676 | | **Diluted EPS** | $0.64 | $0.30 | $1.16 | $0.48 | [Consolidated Statements of Cash Flows](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Net cash from operating activities for H1 2021 increased to **$46.9 million**, while net cash used in investing activities rose to **$26.2 million**, primarily for capital expenditures Cash Flow Summary for Six Months Ended June 30 (in thousands) | Activity | 2021 | 2020 | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $46,913 | $26,265 | | **Net cash used in investing activities** | $(26,198) | $(9,517) | | **Net cash provided by financing activities** | $852 | $5,402 | | **Net increase in cash** | $17,035 | $22,957 | [Notes to Unaudited Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Unaudited%20Consolidated%20Financial%20Statements) These notes detail significant accounting policies, fair value measurements, recent business acquisitions, revenue recognition, goodwill, intangible assets, convertible senior notes, stock-based compensation, income taxes, segment reporting, and subsequent events - The company acquired ARTeSYN for approximately **$204.0 million**, NMS for **$16.1 million**, and EMT for **$28.5 million**, significantly expanding its single-use technology portfolio. These acquisitions were accounted for as business combinations[36](index=36&type=chunk)[47](index=47&type=chunk)[56](index=56&type=chunk) - The **0.375%** Convertible Senior Notes due 2024 became convertible at the option of the holders during Q3 2021, as the company's stock price exceeded the conversion price threshold. The company intends to settle the par value in cash[78](index=78&type=chunk)[97](index=97&type=chunk) - Subsequent to the quarter end, on July 1, 2021, the company closed the acquisition of Polymem S.A., a French manufacturer of hollow fiber membranes, to expand its manufacturing capacity in Europe[106](index=106&type=chunk)[107](index=107&type=chunk) Revenue by Geographic Region (Six Months Ended June 30) | Region | 2021 | 2020 | | :--- | :--- | :--- | | North America | 42% | 47% | | Europe | 39% | 39% | | APAC/Other | 19% | 14% | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=26&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's strong financial performance, driven by robust demand for bioprocessing products, highlighting **87.0%** revenue growth, improved gross margins, increased operating expenses, liquidity, capital resources, and non-GAAP financial reconciliations [Overview and Acquisitions](index=26&type=section&id=Overview%20and%20Acquisitions) Repligen, a global life sciences company, strategically expanded its bioprocessing portfolio through acquisitions of ARTeSYN, NMS, and EMT in 2020, and Polymem S.A. in July 2021, enhancing single-use systems and manufacturing capacity - The company's strategy involves both organic growth and targeted acquisitions to enhance its bioprocessing product platform[111](index=111&type=chunk) - Acquired ARTeSYN in December 2020 for **~$200 million** to add a suite of single-use systems for chromatography, filtration, and continuous manufacturing[114](index=114&type=chunk)[115](index=115&type=chunk) - Acquired Polymem S.A. in July 2021 to substantially increase membrane manufacturing capacity and establish a center of excellence in Europe[112](index=112&type=chunk)[113](index=113&type=chunk) [Results of Operations](index=27&type=section&id=Results%20of%20Operations) Total revenue for H1 2021 grew **87.0%** to **$305.8 million**, driven by strong demand, leading to improved gross margin of **60.2%** despite increased operating expenses from acquisitions and growth investments Revenue Growth (H1 2021 vs H1 2020) | Metric | H1 2021 | H1 2020 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | **Product Revenue** | $305,657 | $163,492 | $142,165 | 87.0% | | **Total Revenue** | $305,797 | $163,552 | $142,245 | 87.0% | - Revenue growth was driven by accelerated demand for products used in COVID-19 vaccine and therapeutic manufacturing, as well as in gene therapy and monoclonal antibody production[128](index=128&type=chunk) - Gross margin for H1 2021 was **60.2%** (**60.7%** excluding inventory step-up charges), up from **57.9%** in H1 2020, due to higher revenue and favorable product mix[132](index=132&type=chunk) - SG&A expenses for H1 2021 increased by **53.9%** to **$83.4 million**, partly due to the addition of EMT, NMS, and ARTeSYN, which contributed **$6.8 million** of the increase[138](index=138&type=chunk) [Non-GAAP Financial Measures](index=30&type=section&id=Non-GAAP%20Financial%20Measures) The company presents non-GAAP financial measures, including adjusted income from operations of **$102.3 million**, adjusted net income of **$83.6 million** (**$1.47** per diluted share), and adjusted EBITDA of **$108.4 million**, to provide a clearer view of operational performance Reconciliation of GAAP Net Income to Adjusted EBITDA (H1 2021 vs H1 2020, in thousands) | Metric | H1 2021 | H1 2020 | | :--- | :--- | :--- | | **GAAP net income** | $65,683 | $25,676 | | Adjustments (Interest, Taxes, D&A, etc.) | $25,956 | $18,225 | | **EBITDA** | $101,051 | $43,929 | | Other non-GAAP adjustments | $7,371 | $4,687 | | **Adjusted EBITDA** | $108,422 | $48,616 | Reconciliation of GAAP to Non-GAAP Adjusted Net Income (H1 2021 vs H1 2020, in thousands) | Metric | H1 2021 | H1 2020 | | :--- | :--- | :--- | | **GAAP net income** | $65,683 | $25,676 | | Non-GAAP adjustments | $17,947 | $13,592 | | **Non-GAAP adjusted net income** | $83,630 | $39,268 | | **Non-GAAP adjusted diluted EPS** | $1.47 | $0.74 | [Liquidity and Capital Resources](index=32&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2021, the company held **$734.3 million** in cash, with **$46.9 million** from operations, and believes its liquidity is sufficient for the next **24 months**, despite **$26.2 million** in capital expenditures and new facility leases - Cash and cash equivalents stood at **$734.3 million** at June 30, 2021[153](index=153&type=chunk) - Cash provided by operating activities for H1 2021 was **$46.9 million**, driven by **$65.7 million** in net income, offset by increases in accounts receivable and inventory[159](index=159&type=chunk) - The company entered into a lease for **~64,000 sq. ft.** in Hopkinton, MA for a new assembly center, with base rent commitment of **$17.7 million** over the lease term expiring in 2034[157](index=157&type=chunk) - The company believes current cash is adequate for at least the next **24 months**, but may seek additional financing for strategic acquisitions[164](index=164&type=chunk)[165](index=165&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=35&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's market risk primarily stems from interest rate and foreign exchange fluctuations, with no commercial paper or bond investments, and unhedged exposure to the Swedish krona, Euro, and British pound - The company has no investments in commercial paper, corporate bonds, or other debt securities as of June 30, 2021, thus a **100 basis point** change in interest rates would have no effect on its cash position[170](index=170&type=chunk) - The company is exposed to foreign currency fluctuations, primarily from the Swedish krona, Euro, and British pound, and does not currently hedge this risk[173](index=173&type=chunk) [Controls and Procedures](index=36&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective, with ongoing phased implementation of a new ERP system and completed consolidation system leading to modifications in internal controls over financial reporting - Management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of the end of the quarter[174](index=174&type=chunk) - The company continued the phased implementation of a new ERP system and completed a new consolidation system, leading to modifications in internal controls over financial reporting[175](index=175&type=chunk) PART II - OTHER INFORMATION [Legal Proceedings](index=37&type=section&id=Item%201.%20Legal%20Proceedings) The company reports no material legal proceedings or claims that would adversely affect its business, financial condition, or results of operations - The company reports no material legal proceedings[177](index=177&type=chunk) [Risk Factors](index=37&type=section&id=Item%201A.%20Risk%20Factors) No material changes to the risk factors previously disclosed in the company's Annual Report on Form 10-K for the period ended December 31, 2020 are reported - No material changes to risk factors from the Form 10-K for the period ended December 31, 2020 are reported[178](index=178&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=37&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities or use of proceeds during the period - None[179](index=179&type=chunk) [Exhibits](index=38&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including CEO and CFO certifications and XBRL data files - Exhibits filed include CEO and CFO certifications (31.1, 31.2, 32.1) and XBRL interactive data files[183](index=183&type=chunk)

Repligen Corp, Inc. (NASDAQ:RGEN) Q2 2021 Earnings Conference Call July 27, 2021 8:30 AM ET Company Participants Sondra Newman - Global Head, IR Anthony Hunt - CEO, President & Director Jon Snodgres - CFO Conference Call Participants Daniel Arias - Stifel, Nicolaus & Company Puneet Souda - SVB Leerink John Kreger - William Blair & Company Julia Qin - JPMorgan Chase & Co. Jacob Johnson - Stephens Inc. Matthew Hewitt - Craig-Hallum Paul Knight - KeyBanc Capital Markets Raghuram Selvaraju - H.C. Wainwright & C ...

Table of Contents FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (I.R.S. Employer Identification No.) (781) 250-0111 Registrant's Telephone Number, Including Area Code Securities r ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 04-2729386 (State or other jurisdic ...

Repligen Corporation (NASDAQ:RGEN) Q4 2020 Earnings Conference Call February 24, 2021 8:30 AM ET Company Participants Sondra Newman - Global Head of IR Tony J. Hunt - President and CEO Jon K. Snodgres - CFO Conference Call Participants Dan Arias - Stifel Unidentified Analyst - J.P. Morgan Paul Knight - KeyBanc Capital Jacob Johnson - Stephens, Inc. Matthew Hewitt - Craig-Hallum Puneet Souda - SVB Leerink Brandon Couillard - Jefferies Inc Raghuram Selvaraju - H.C. Wainwright Operator Good day ladies and gent ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-14656 REPLIGEN CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 04-2729386 (State or Other ...

Repligen Corporation (NASDAQ:RGEN) Q3 2020 Earnings Conference Call November 5, 2020 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Puneet Souda - SVB Leerink John Kreger - William Blair Matt Hewitt - Craig Hallum Operator Good day, and welcome to the Repligen Corporation's Third Quarter 2020 Earnings Conference Call. My name Danielle, an ...

Repligen Corporation (NASDAQ:RGEN) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Financial Corp. Puneet Souda - SVB Leerink LLC Tycho Peterson - JPMorgan Chase & Co. Jacob Johnson - Stephens Inc. John Kreger - William Blair & Company Matthew Hewitt - Craig-Hallum Capital Group LLC Operator G ...